. 
(See accompanying Excel file). Representative proteomic data (Related to
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Competitive Gel-Based ABPP
In vitro and in situ competitive gel-based ABPP was performed as described previously (Chang et al., 2013; Hsu et al., 2012) . Briefly, after in vitro (30 min, 37 °C) or in situ (described above) inhibitor or DMSO treatment, cell lysates were subjected to gel-based ABPP analysis.
In Vivo Administration of Inhibitors
Mice were injected with ABC44, ABC51, JJH254, or vehicle, as described previously (Chang et al., 2013; Hsu et al., 2012) . Briefly, C57Bl/6 mice were injected 
IsoTOP Site-of-Labeling of PPT1 by ABC45
Whole cell lysates (500 µL, 1.5 mg/mL) of hPPT1 transfected HEK239Ts were processed for MS analysis using the previously described isoTOP-ABPP protocol (Weerapana et al., 2010) . In brief, for analysis of ABC45-modified peptides, proteomes were split into two fractions, to which ABC45 (5 µM, 60 min) or DMSO was added. The lysates were then subjected to Click Chemistry-ABPP conditions with either light (ABC45 treated samples) or heavy (DMSO treated samples) isotopically labeled TEV-tags. Light and heavy-tagged proteomes were then combined, and, following enrichment of probelabeled targets using streptavidin beads, proteins were digested on-bead with trypsin and the remaining immobilized peptides were subsequently released with TEV protease.
The resulting probe-modified peptides were pressure loaded onto a 100 µm (inner diameter) fused silica capillary column with a 5 µm tip containing 10 cm C18 resin (5 µm, Phenomenex), eluted with a 180 min gradient from 0% to 100% Buffer B (Buffer A: 5% acetonitrile, 95% water, 0.1% formic acid; Buffer B: 80% acetonitrile, 20% water, 0.1% formic acid), and collected for MS analysis on an LTQ-Orbitrap. Samples were then searched as described above. The mass of the modification used to search for probemodified peptides was +626.3289 m/z for the probe adduct plus the light TEV-tag and +632.3427 m/z for the heavy counterpart. MS1 peaks for probe-labeled quantified peptides were extracted with Xcalibur Qual Browser 2.2 (Thermo Scientific).
Transient Overexpression of Proteins
HEK293T cells were seeded at 2 x 10 5 per well on 6 well plates and grown for 48 h.
They were then transfected with mouse ABHD3 (pCMV-Sport6), human ABHD4 (pcDNA3.1/myc-his), human PPT1 (pCMV6-XL5), or human PPT1-S115A (pCMV6-XL5)
cDNA-containing vectors, by incubating 0.5 µg of DNA with 3 µL of PEI MAX (1 mg/mL, Polysciences, Inc.) in serum-free DMEM for 30 min, then adding them to cells. After 48 h cells were either treated with compound in situ, as described above, or harvested for in vitro studies. The S110A PPT1 mutation was introduced using QuikChange II Site Directed Mutagenesis Kit (Agilent) with the following primers:
hPPT1 S->A QC Forward: aattggcctccctgggcgaatcccatagcattg hPPT1 S->A QC Reverse: caatgctatgggattcgcccagggaggccaatt
Western Blotting
Following SDS-PAGE, PPT1 samples were transferred to nitrocellulose for 2 h at 50 V.
Transfers were then washed, blocked with 5% milk, and incubated overnight with an anti-PPT1 antibody (Abcam ab89022, 1:2000 in TBS-T with 5% milk). Transfers were then washed with TBS-T (3x) and incubated with a secondary antibody (Odyssey 926-23310, 1:5000 in TBS-T with 5% milk) for 2 h. Transfers were then washed again (3x, TBS-T) and imaged on a Li-cor Odyssey (Model 9120).
PPT1 Substrate Assay
PPT1 activity was assessed in vitro using a substrate assay adapted from previous studies (van Diggelen et al., 1999) . Lysates from HEK293T cells transfected with an empty vector, or human PPT1 under a CMV promoter were adjusted to 1 mg/mL in PBS 
Cell Viability Assay
The cytotoxicity of ABC44 and ABC51 against HeLa cells was assayed as previously described (Hulce et al., 2014 Spectrometry. All compounds were prepared as racemates. eq) and N-methylmorpholine (1.31 mL, 1.1 eq) in CH 2 Cl 2 (55 mL) was added carbonyldiimidazole (1.76 g, 1 eq). The resulting solution was stirred to room temperature for 2 h. At this time, 4-Boc-piperazine-2-carboxylic acid (2.0 g, 8.67 mmol, 0.8 eq) was added all at once, followed by additional NMM (1.91 mL, 1.6 eq). The resulting suspension was stirred for 24 h at room temperature, at which time moisture was notably generated in the reaction vessel; sodium sulfate was added, followed by 
General Synthetic Scheme
tert-butyl 2-hydroxy-1,3-dioxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate:
The bis-protected N-hydroxyhydantoin (300 mg, 0.831 mmol, 1 eq) was dissolved in EtOAc (4 mL), and palladium on carbon (10% w/w) (85 mg, ~10 mol%) was added. The 
3-(benzyloxy)-5-isopropylimidazolidine-2,4-dione: To a stirring solution of N-Boc-L-
valine (337 mg, 1.55 mmol, 1 eq), O-benzylhydroxylamine hydrochloride (272 mg, 1.1 eq) and N-methylmorpholine (171 µL, 1 eq) in anhydrous CH 2 Cl 2 (10 mL) under nitrogen was added EDCI (327 mg, 1.1 eq) at 0 ºC. After stirring for 1 h, the reaction was allowed to warm to room temperature and stirred for an additional 4 h. The reaction was quenched with ice cold 5% aqueous HCl (10 mL) and the product was extracted with CH 2 Cl 2 (3 x 25 mL). The combined organic layers were washed with brine (2 x 25 mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure to provide the crude product which was deprotected upon addition of HCl (5 mL, 4 N in 1,4-dioxane).
After 1 h at room temperature, the deprotected amino amide was concentrated under a stream of N 2 and then under reduced pressure. The remaining residue was dissolved in anhydrous CH 2 Cl 2 (50 mL) and to this solution was added NMM (341 µL, 2.0 eq) followed by 1,1'-carbonyldiimidazole (277 mg, 1.1 eq) at room temperature. After stirring the reaction mixture overnight, the reaction was poured into a separatory funnel containing ice cold 5% aqueous HCl (50 mL) and the product was extracted with CH 2 Cl 2 (3 x 50 mL). (4-(4-chlorophenethyl)piperidin-1-yl)(1H-imidazol-1-yl)methanone: 4-chlorophenethylpiperidine hydrochloride (520 mg, 2 mmol, 1 eq) was suspended in 10 mL methylene chloride, triethylamine (404 mg, ~2 eq) was added, and the resulting solution was cooled to 0 o C. At this time, carbonyldiimidazole (389 mg, 1.2 eq) was added all at once. The resulting mixture was stirred to room temperature over night. At this time, the mixture was concentrated to a residue, dissolved in EtOAc (with 5% MeOH v/v) and transferred to a separatory funnel, washed successively with water, 0.2 N aq.
LiOH, and water again, dried (Na 2 SO 4 ) and concentrated in vacuo to yield the imidazole urea as an off-white solid (439 mg, 69%) that was used without further purification. g, 74.1 mmol, 1 eq) was dissolved in 120 mL dry THF, and pyridine (30 mL, ~5 eq) was added, and the resulting solution was cooled to 0 o C. At this time, triphosgene (11 g, 0.5 eq) was added in small portions. The resulting mixture was allowed to warm to room temperature and was stirred overnight. 
tert-butyl 2-((4-(4-methoxyphenyl)piperazine-1-carbonyl)oxy)-1,3-dioxohexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxylate (MJN202; Compound 3):
The free N-Boc-NHH (200 mg, 0.737 mmol, 1 eq) was dissolved in 3.5 mL dry THF, and triethylamine (225 mg, 3 eq) and a catalytic amount of 4-DMAP, followed by 4-MeO-Phpiperazine carbamyl chloride (188 mg, 1 eq) at room temperature. The solution was heated at 60 o C for 2 h, filtered, and concentrated to a residue in vacuo that was Bocdeprotected without further purification (267 mg, 93% over two steps). A sample was separated by prep-TLC (60% EtOAc/hexanes) for analysis to yield an off-white solid. 
1,3-dioxohexahydroimidazo[1,5-a]pyrazin-2(3H)-yl 4-(4-chloro
1-(1,3-dioxohexahydroimidazo[1,5-a]pyrazin-2(3H)-yl) 4-methyl piperidine-1,4-dicarboxylate hydrochloride (JJH257): JJH238 was Boc deprotected using methanolic
HCl as described for JJH222, yielding a white solid, which was used without further 
1,3-dioxohexahydroimidazo[1,5-a]pyrazin-2(3H)-yl 4-(4-methoxyphenyl)piperazine-
1-carboxylate hydrochloride (JJH331):
MJN202 was Boc-deprotected using 
1,3-dioxo-7-(piperidin-4-ylmethyl)hexahydroimidazo[1,5-a]pyrazin-2(3H)-yl 4-(4-methoxyphenyl)piperidine-1-carboxylate hydrochloride (ABC38; Compound 15):
ABC37 was Boc-deprotected using methanolic HCl as described for JJH222, yielding a yellow solid, which was used without further purification. formaldehyde (6 µl, 37% wt. in water, 1.5 eq), acetic acid (2.8 µl, 1eq) and sodium triacetoxyborohydride (11 mg, 1.1 eq) were added at room temperature. The resulting suspension was stirred at room temperature overnight, concentrated to a residue, and separated by prep-TLC (EtOAc + 1% Et 3 N) to yield MJN200 as an off-white solid (12 mg, 63% 1-benzylpiperidin-4-yl)methyl)-1,3-dioxohexahydroimidazo[1,5-a]pyrazin-2(3H)-yl 4-(4-methoxyphenyl) 
1-(4-(prop-2-yn-1-yloxy)phenyl)piperazine hydrochloride:
Tert-butyl 4-(4-(prop-2-yn-1-yloxy)phenyl)piperazine-1-carboxylate was Boc deprotected using methanolic HCl as described for JJH222, yielding an off-white solid that was used without further purification. 1H NMR (D2O, 500 MHz) δ 7. The free N-Boc-NHH (9.5 mg, 35.2 µmol, 1.1 eq) was dissolved in 0.35 mL THF, and triethylamine (13 µl, 96 µmol, 3 eq) was added, followed by (1H-imidazol-1-yl)(4-(4-(prop-2-yn-1-yloxy)phenyl)piperazin-1-yl)methanone (10 mg, 32 µmol, 1 eq) at room µmol, 4 eq) was added followed by sodium triacetoxyborohydride (12.2 mg, 54 µmol, 2 eq). The resulting mixture was stirred at room temperature over night, concentrated and separated by prep-TLC (50% EtOAc/hexanes) to yield ABC45 as a clear oil (11.6 mg, 
